Similar articles

• Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.

  Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, Gu F, Auchus R, Leelawattana R, Lee EJ, Kim JH, Lacroix A, Laplanche A, O'Connell P, Tauchmanova L, Pedroncelli AM, Biller BMK; LINC 3 investigators. Pivonello R, et al. Lancet Diabetes Endocrinol. 2020 Sep;8(9):748-761. doi: 10.1016/S2213-8587(20)30240-0. Epub 2020 Jul 27. Lancet Diabetes Endocrinol. 2020. PMID: 32730798 Clinical Trial.
• Effectiveness of Medical Treatment of Cushing's Disease: A Systematic Review and Meta-Analysis.

  Simões Corrêa Galendi J, Correa Neto ANS, Demetres M, Boguszewski CL, Nogueira VDSN. Simões Corrêa Galendi J, et al. Front Endocrinol (Lausanne). 2021 Sep 17;12:732240. doi: 10.3389/fendo.2021.732240. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34603209 Free PMC article.
• Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.

  Varlamov EV, Han AJ, Fleseriu M. Varlamov EV, et al. Best Pract Res Clin Endocrinol Metab. 2021 Jan;35(1):101490. doi: 10.1016/j.beem.2021.101490. Epub 2021 Feb 6. Best Pract Res Clin Endocrinol Metab. 2021. PMID: 33707082 Review.
• Osilodrostat: A Novel Steroidogenesis Inhibitor to Treat Cushing's Disease.

  Dougherty JA, Desai DS, Herrera JB. Dougherty JA, et al. Ann Pharmacother. 2021 Aug;55(8):1050-1060. doi: 10.1177/1060028020968808. Epub 2020 Nov 3. Ann Pharmacother. 2021. PMID: 33143437
• Advances in pharmacological treatment of Cushing's disease.

  Chai J, Tang Y, Liu Y, Tan H, Li J. Chai J, et al. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 Jul 28;49(7):1023-1033. doi: 10.11817/j.issn.1672-7347.2024.240306. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024. PMID: 39788490 Free PMC article. Review. Chinese, English.